Validity of a smartphone app to objectively monitor performance outcomes in degenerative cervical myelopathy: an observational study

• DOI: 10.1101/2023.09.13.23294900
• Publication Date: 2023-09-14T03:45:20Z
• Authors: Alvaro Yanez Touzet; Tatiana Houhou; Zerina Rahic; Ilya Laufer; Konstantinos Marg...; Allan R Martin; Nicolas Dea; Zoher Ghogawala; Misha Kapushesky; Mark R N Kotter; Benjamin M. Davies

ABSTRACT Objectives To assess the validity of MoveMed, a battery performance outcome measures performed using mobile phone application, in measurement degenerative cervical myelopathy (DCM). Design Prospective observational study. Setting Decentralised secondary care England, United Kingdom. Participants 27 adults aged 60 (SD: 11) who live with DCM and possess an approved smartphone. Primary Criteria from Consensus-based Standards for selection health Measurement Instruments (COSMIN) manual were used to risk bias. Briefly, each MoveMed was compared two patient-reported comparators, priori hypotheses convergence/divergence tested against consensus thresholds. The primary correlation coefficient between comparators. percent correlations correspondence hypotheses. comparators patient-derived modified Japanese Orthopaedic Association (P-mJOA) score World Health Organization Quality Life Brief Version (WHOQOL-Bref) questionnaire. Thresholds ≥0.3/<0.3, >0/<0 directionality. Results As expected, MoveMed’s tests neuromuscular function correlated most questionnaires (≥0.3) least quality life (<0.3). Furthermore, directly related constructs positively other (>0), while inversely negatively (<0). Over 70% 50% (unidimensional multidimensional, respectively) accordance No bias factors COSMIN Risk Bias checklist recorded. Overall, this equivalent ‘very good’ evidence sufficient construct DCM. Conclusions provide adult population living